bluebird bio Inc. (NASDAQ: BLUE) is -40.24% lower on its value in year-to-date trading and has touched a low of $2.87 and a high of $17.85 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BLUE stock was last observed hovering at around $6.17 in the last trading session, with the day’s loss setting it -0.2% off its average median price target of $9.00 for the next 12 months. It is also 40.3% off the consensus price target high of $10.00 offered by 11 analysts, but current levels are -99.0% lower than the price target low of $3.00 for the same period.
Currently trading at $5.97, the stock is -8.21% and 3.78% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 6.54 million and changing -3.24% at the moment leaves the stock 1.35% off its SMA200. BLUE registered -48.68% loss for a year compared to 6-month gain of 24.12%.
The stock witnessed a 1.36% loss in the last 1 month and extending the period to 3 months gives it a 39.49%, and is -15.80% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 14.27% over the week and 9.91% over the month.
bluebird bio Inc. (BLUE) has around 518 employees, a market worth around $514.91M and $6.10M in sales. Distance from 52-week low is 108.38% and -66.55% from its 52-week high. The company has generated returns on investments over the last 12 months (-157.90%).
bluebird bio Inc. (BLUE) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for bluebird bio Inc. (BLUE) is a “Hold”. 11 analysts offering their recommendations for the stock have an average rating of 3.10, where 8 rate it as a Hold and 1 think it is a “Overweight”. 0 of the analysts rate the stock as a “Buy”. 2 analysts have rated the stock as a Sell or Underperform.
bluebird bio Inc. is expected to release its quarterly report on 11/03/2022.The EPS is expected to grow by 9.50% this year
bluebird bio Inc. (BLUE) Top Institutional Holders
The shares outstanding are 77.12M, and float is at 76.22M with Short Float at 25.90%.
bluebird bio Inc. (BLUE) Insider Activity
A total of 12 insider transactions have happened at bluebird bio Inc. (BLUE) in the last six months, with sales accounting for 5 and purchases happening 7 times. The most recent transaction is an insider sale by Cole Jason, the company’s Chief Strategy & Financial Off. SEC filings show that Cole Jason sold 14,194 shares of the company’s common stock on Aug 19 at a price of $5.53 per share for a total of $78473.0. Following the sale, the insider now owns 0.19 million shares.
bluebird bio Inc. disclosed in a document filed with the SEC on Aug 04 that Cole Jason (Chief Strategy & Financial Off) sold a total of 7,448 shares of the company’s common stock. The trade occurred on Aug 04 and was made at $4.39 per share for $32707.0. Following the transaction, the insider now directly holds 0.2 million shares of the BLUE stock.
Still, SEC filings show that on Aug 04, Obenshain Andrew (President and CEO) disposed off 21,805 shares at an average price of $4.39 for $95754.0. The insider now directly holds 247,131 shares of bluebird bio Inc. (BLUE).
bluebird bio Inc. (BLUE): Who are the competitors?
The company’s main competitors (and peers) include Sangamo Therapeutics Inc. (SGMO) that is trading -47.50% down over the past 12 months and Ionis Pharmaceuticals Inc. (IONS) that is 23.00% higher over the same period. Sanofi (SNY) is -18.85% down on the 1-year trading charts.